User login
The treatment of patients with hemophilia has rapidly evolved from one-size-fits-all factor replacement strategies to highly individualized, patient-specific care.
Faculty:
Erik Berntorp, MD, PhD
Malmö Centre for Thrombosis and Haemostasis
Lund University
Malmö, Sweden
Faculty Disclosures:
This sponsored content was prepared by Dr. Berntorp and reviewed by Shire. Dr. Berntorp discloses that he is a consultant and on the advisory boards and speakers’ bureaus for Bayer, CSL Behring, Octapharma, Shire, and Sobi. The production of this section did not involve the news or editorial staff of Frontline Medical Communications.
S28001
2/17
Click here to read the supplement
The treatment of patients with hemophilia has rapidly evolved from one-size-fits-all factor replacement strategies to highly individualized, patient-specific care.
Faculty:
Erik Berntorp, MD, PhD
Malmö Centre for Thrombosis and Haemostasis
Lund University
Malmö, Sweden
Faculty Disclosures:
This sponsored content was prepared by Dr. Berntorp and reviewed by Shire. Dr. Berntorp discloses that he is a consultant and on the advisory boards and speakers’ bureaus for Bayer, CSL Behring, Octapharma, Shire, and Sobi. The production of this section did not involve the news or editorial staff of Frontline Medical Communications.
S28001
2/17
Click here to read the supplement
The treatment of patients with hemophilia has rapidly evolved from one-size-fits-all factor replacement strategies to highly individualized, patient-specific care.
Faculty:
Erik Berntorp, MD, PhD
Malmö Centre for Thrombosis and Haemostasis
Lund University
Malmö, Sweden
Faculty Disclosures:
This sponsored content was prepared by Dr. Berntorp and reviewed by Shire. Dr. Berntorp discloses that he is a consultant and on the advisory boards and speakers’ bureaus for Bayer, CSL Behring, Octapharma, Shire, and Sobi. The production of this section did not involve the news or editorial staff of Frontline Medical Communications.
S28001
2/17
Click here to read the supplement
